Drug Profile
Research programme: small molecule therapeutics - Disarm Therapeutics
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Washington University
- Developer Disarm Therapeutics
- Class Antiglaucomas; Neuroprotectants; Small molecules
- Mechanism of Action SARM1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Glaucoma; Multiple sclerosis; Neurological disorders; Peripheral nervous system diseases
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 28 Oct 2021 No recent reports of development identified for preclinical development in Glaucoma in USA
- 28 Oct 2021 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA